Table 2.
Analysis of risk factors associated with variceal eradication
| Risk factors | Variceal eradication complete (n = 59) | Variceal eradication incomplete (n = 38) | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p value | OR | 95% CI | p value | |||
| Male gender (%) | 47 (79.7) | 28 (73.7) | 0.7 | 0.3–1.9 | 0.493 | |||
| Age (mean±SD), years | 58.7±11.5 | 60.5±13.8 | 0.491 | |||||
| Etiology eradication (%) | 33/49 (67.3) | 21/29 (72.4) | 1.3 | 0.5–3.5 | 0.639 | |||
| Child-Pugh B/C (%) | 14/53 (26.4) | 9/32 (28.1) | 1.1 | 0.4–2.9 | 0.863 | |||
| MELD-Na, median (IQR) | 11.0 (8.3–14.0) | 11.0 (9.75–15.0) | 0.348 | |||||
| PVT (%) | 9 (15.2) | 13 (34.2) | 0.3 | 0.1–0.9 | 0.030 | 2.9 | 0.9–9.4 | 0.077 |
| HCC (%) | 5 (8.5) | 4 (10.5) | 0.8 | 0.2–3.1 | 0.734 | |||
| NSBBs (%) | 35 (59.3) | 27/37 (73.0) | 0.5 | 0.2–1.3 | 0.173 | |||
| Platelets 109/L, median (IQR) | 82.0 (57.0–144.0) | 90.5 (66.0–133.5) | 0.779 | |||||
| Nr.EBL sessions (mean±SD) | 3.7±1.4 | 4.7±2.6 | 0.028 | 0.8 | 0.6–0.9 | 0.048 | ||
| Secondary prophylaxis (%) | 34 (57.6) | 32 (84.2) | 0.3 | 0.1–0.7 | 0.006 | 3.0 | 0.9–9.7 | 0.068 |
| Severe PHG (%) | 25 (42.4) | 14 (36.8) | 1.3 | 0.5–2.9 | 0.588 | |||
| Pandemic group (%) | 18 (30.5) | 26 (68.4) | 0.2 | 0.08–0.5 | <0.001 | 4.9 | 1.8–13.3 | 0.002 |
SD, standard deviation; MELD, model of end-stage liver disease; PVT, portal vein thrombosis; HCC, hepatocellular carcinoma; NSBBs, nonselective β-blockers; EBL, endoscopic band ligation; IQR, interquartile range; PHG, portal hypertensive gastropathy.